1941 - 1950 of 4301 Drugs
Vaniqa (eflornithine)
Vaniqa (eflornithine hydrochloride) Cream is used to reduce unwanted facial hair in women. It blocks a certain enzyme needed for hair growth in the skin. This effect slows hair growth and may also make the hair finer and lighter. Vaniqa Cream It does not remove hair or cause the hair to fall out.
Efudex (fluorouracil)
Efudex (fluorouracil) topical contains an antineoplastic antimetabolite used to treat scaly overgrowths of skin (actinic or solar keratoses). Efudex may also be used in the treatment of superficial basal cell carcinoma. It works by causing the death of cells that are growing fastest, such as abnormal skin cells. Efudex is available in generic form.
Egaten (triclabendazole tablets)
Egaten (triclabendazole) is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.
Egrifta (tesamorelin injection)
Egrifta (tesamorelin) for Injection is made with growth hormone-releasing factor (GRF) and is used to reduce excess fat around the stomach that is caused by taking certain HIV medications. This condition is called lipodystrophy. Egrifta is not a weight-loss medication and should not be used to treat obesity.
Egrifta SV (tesamorelin for injection)
Egrifta SV (tesamorelin kit) is a growth hormone releasing factor (GHRF) analog used to reduce excess abdominal fat in HIV-infected adult patients with lipodystrophy.
Zovia (etynodiol diacetate and ethinyl estradiol tablets)
Zovia (ehtynodiol diacetate and ethinyl estradiol tablets) contains a combination of female hormones and is used as contraception to prevent pregnancy. Zovia is available in generic form.
Orserdu (elacestrant tablets)
Orserdu (elacestrant) is an estrogen receptor antagonist indicated for treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Orilissa (elagolix tablets)
Orilissa (elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the management of moderate to severe pain associated with endometriosis.
Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules)
Oriahnn (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules) is a combination of a gonadotropin-releasing hormone (GnRH) receptor antagonist, an estrogen, and a progestin used to manage heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. Use of Oriahnn should be limited to 24 months due to the risk of continued bone loss, which may not be reversible.
Elahere (mirvetuximab soravtansine-gynx injection)
Elahere (mirvetuximab soravtansine-gynx) is a folate receptor alpha (FRα)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.